Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-03-14
2004-03-02
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S175000, C536S053000, C536S055000, C536S055100, C536S123130
Reexamination Certificate
active
06699846
ABSTRACT:
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
Damage caused to tissues during ischemia/reperfusion can be extensive. Tissues deprived of oxygen suffer both reversible and irreversible damage. Injured tissues can also display disorders in automaticity. For example, myocardial tissues damaged during ischemia/reperfusion can display irreversible damage or myocardial infarction. Reversible damage, or stunning, is apparent with reduced pump efficiency leading to decreased cardiac output and symptomatology of suboptimal organ perfusion. Reperfusion of ischemic myocardial tissue may also cause electrophysiologic changes causing disorders in automaticity, including lethal arrhythmias.
The exact mechanisms by which tissues are damaged during ischemia/reperfusion are unknown. It is hypothesized, however, that a complex series of events occur where tissues are damaged during ischemia as well as during subsequent reperfusion. During ischemia, tissues are deprived of oxygen-giving blood leading to anaerobic metabolism and consequently intracellular acidosis. Lack of circulation can cause infarcts or areas of necrotic, dead tissue. Ischemic tissues produce less of the enzymes needed to scavenge free radicals. Upon reperfusion and re-exposure to oxygen, tissues are damaged when free radicals including hydroxyl radicals are produced. Oxidative damage also disrupts the calcium balance in surrounding tissues causing stunning. Damage due to the oxidative burst is further compounded when injured cells release factors which draw inflammatory neutrophils to the ischemic site. The inflammatory cells produce enzymes which produce more toxic free-radicals and infiltrate the interstitial spaces where they kill myocytes.
Methods to protect against the damage due to ischemia/reperfusion injury focus on reducing anaerobic metabolism as well as the initial oxidative burst and ensuing calcium overload preventing subsequent inflammation-associated damage. For example, agents which either decrease the production of oxygen-derived free radicals (including allopurinol and deferoxamine) or increase the catabolism of these materials such as superoxide dismutase, catalase, glutathione, and copper complexes, appear to limit infarct size and also may enhance recovery of left ventricular function from cardiac stunning. Agents which block sarcolemmal sodium/hydrogen exchange such as amiloride prevent the obligatory influx of calcium into the cell attendant with sodium extrusion and consequently reduce calcium overload.
Tissues can also be protected from ischemia/reperfusion injury by ischemic preconditioning. Ischemic preconditioning is triggered by brief antecedent ischemia followed by reperfusion which results in the rapid development of ischemic tolerance. This acute preconditioned state of ischemic tolerance lasts 30 min to 2 h and in myocardial tissue is characterized by reduced infarct size and a reduced incidence of ventricular arrhythmias but not reduced levels of stunning (Elliott,
J. Mol. Cell Cardiol.,
30(1):3-17 (1998)). Following dissipation of the acute preconditioned state, even in the absence of additional periods of preconditioning ischemia, a delayed preconditioned state of ischemic tolerance appears 12-24 h later and lasts up to 72 h. During the delayed phase of preconditioning protection against myocardial infarction, stunning and arrhythmia have been reported in various species.
Features of preconditioned myocardium in the face of ischemia/reperfusion include preservation of adenosine triphosphate (ATP) in some models, attenuation of intracellular acidosis and the reduction of intramyocyte calcium loading. Certain chemical agents known to be released by myocardium during ischemia have been shown to induce acute and delayed ischemic tolerance and provide cardiac protection. For example, adenosine, bradykinin and opiate receptor agonists which induce acute preconditioning and appear to protect from ischemic injury via ATP dependent potassium (K
ATP
) channel signaling pathways. The agent, bimakalim, known to open the K
ATP
channel has also been shown to limit infarct size (Mizumura et al.,
Circulation,
92:1236-1245 (1995)). Monophosphoryl lipid A (MLA) prevents irreversible as well as reversible damage to ischemic tissues (Elliot U.S. Pat. No. 5,286,718). Monophosphoryl lipid A is a detoxified derivative of lipid A, the active substructural element of lipopolysaccharide (LPS). LPS or endotoxin is a potent immunomodulator produced by most strains of Gram-negative bacteria. Pretreatment with LPS prior to ischemia has been shown to increase myocardial catalase activity increasing myocardial function (Brown et al.,
Proc. Natl. Acad. Sci. U.S.A,
86(7):2516-2520 (1989), Bensard et al.,
J. Surg. Res.,
49(2):126-131 (1990)). Endotoxin also protects against lung injury during hypoxia (Berg et al.,
J Appl. Physiol.,
68(2):549-553 (1990), Berg et al.,
Soc. Exper. Biol. Med.,
167-170 (1990)). The cardioprotective effect of high doses of endotoxin appears to be associated with the ability of this “toxin” to induce upon pretreatment myocardial oxidative stress, thereby protecting from a second oxidative stress associated with ischemia (Maulik et al.,
Am. J. Physiol.,
269:C907-C916 (1995)). LPS however is quite toxic. MLA has been structurally modified to negate the toxicity of LPS. It is hypothesized that MLA protects against injury due to ischemia/reperfusion injury by inducing the production of nitric oxide synthase which leads to an enhanced open-state probability of the cardioprotective ATP-dependent potassium channel (K
ATP
). The nitric oxide burst caused by MLA may also lead to a decrease in the number of inflammatory neutrophils entering the post-ischemic area protecting the patient from further injury. In contrast to endotoxin, MLA does not appear to induce myocardial oxidative stress at cardioprotective doses.
Current treatments for ischemia/reperfusion injury are not however without drawbacks. Many of the agents known to be active, do not have broad clinical applicability, have limited effectiveness, and/or have dose limiting toxicities and consequently have been restricted in their application to ameliorate ischemia/reperfusion injury in the heart. Endotoxin is highly toxic to the system at cardioprotective doses. MLA, while non-toxic, is manufactured by the fermentation of
S. minnesota
and, as is the case with many biological products, exists as a composite or mixture of a number of molecular congeners varying in fatty acid substitution patterns with varying fatty acid chain lengths.
Although in comparison with endotoxin, MLA is non-toxic at cardioprotective doses, MLA can cause mild, transient, although not dose-limiting, fever and flu-like symptoms in the target dose range. It should therefore be apparent from the above that a need remains for new compositions which are safe, effective and which have a broad clinical applicability in preventing or ameliorating the harmful effects of ischemia/reperfusion. Compositions which are non-toxic, non-pyrogenic, produced by chemical synthesis and of a single defined molecular structure would prove advantageous for this application. More specifically, there is a need for compounds which induce or activate nitric oxide signalling in a tissue-selective or specific fashion, wherein the compound upregulates nitric oxide (NO) in target tissues without inducing proinflammatory cytokines or NO at the level of the macrophage/monocyte and without pyrogenic effects. Surprisingly, the present invention provides such compounds.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides methods for treating diseases or conditions mediated by nitric oxide, particularly ischemia and reperfusion injury. The methods comprise administering to a subject in need of such treatment an effective amount of a compound having the formula:
and pharmaceutically acceptable salts thereof, wherein X is —O— or —NH—; R
1
and R
2
are each independently a (C
2
-C
24
)acyl
Elliott Gary T.
Johnson David
Sowell Greg
Weber Patricia
Barts Samuel
Corixa Corporation
Khare Devesh
Townsend and Townsend / and Crew LLP
LandOfFree
Mono- and disaccharides for the treatment of nitric oxide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mono- and disaccharides for the treatment of nitric oxide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mono- and disaccharides for the treatment of nitric oxide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3273103